New perspectives on bioactivity of olive oil: Evidence from animal models, human interventions and the use of urinary proteomic biomarkers

Abstract

Olive oil (OO) is the primary source of fat in the Mediterranean diet and has been associated with longevity and a lower incidence of chronic diseases, particularly CHD. Cardioprotective effects of OO consumption have been widely related with improved lipoprotein profile, endothelial function and inflammation, linked to health claims of oleic acid and phenolic content of OO. With CVD being a leading cause of death worldwide, a review of the potential mechanisms underpinning the impact of OO in the prevention of disease is warranted. The current body of evidence relies on mechanistic studies involving animal and cell-based models, epidemiological studies of OO intake and risk factor, small- and large-scale human interventions, and the emerging use of novel biomarker techniques associated with disease risk. Although model systems are important for mechanistic research nutrition, methodologies and experimental designs with strong translational value are still lacking. The present review critically appraises the available evidence to date, with particular focus on emerging novel biomarkers for disease risk assessment. New perspectives on OO research are outlined, especially those with scope to clarify key mechanisms by which OO consumption exerts health benefits. The use of urinary proteomic biomarkers, as highly specific disease biomarkers, is highlighted towards a higher translational approach involving OO in nutritional recommendations.

Full text

Silva et al 2015 New perspectives on bioactivity of olive oil
1
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
New perspectives on bioactivity of olive oil – evidence from
animal models, human interventions and the use of urinary
proteomic biomarkers
By S. Silva1,2,3, E. Combet4, M.E. Figueira3, T. Koeck5, W. Mullen6 and M.R. Bronze1,2,3, 1iBET,
Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2780-901 Oeiras, Portugal
2 ITQB, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de
Lisboa, Av. da República, 2780-157 Oeiras, Portugal 3Pharmacy Faculty, University of Lisbon,
Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal, 4Human Nutrition, School of Medicine,
University of Glasgow, Glasgow G31 2ER, UK 5 Mosaiques diagnostics GmbH, Mellendorfer
Strabe 7-9, 30625, Hannover, Germany, and 6Institute of Cardiovascular and Medical Sciences,
University of Glasgow, Glasgow G12 8QQ, UK
This is a pre peer review manuscript of the full paper
published in Proceedings of the Nutrition 08/2015; 74(3):268-
281. DOI:10.1017/S0029665115002323
Corresponding author:
M. R. Bronze, Pharmacy Faculty, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisboa,
Portugal; telephone number (+351) 21 794 64 00 Ext. 14329; Fax number (+351) 217946470
email mrbronze@ff.ulisboa.pt.
Short title: New perspectives on bioactivity of olive oil
Keywords: olive oil, phenolics, coronary artery disease, inflammation, proteomic
biomarkers

Silva et al 2015 New perspectives on bioactivity of olive oil
2
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
Abstract
Olive oil (OO) is the primary source of fat in the Mediterranean diet and has been associated
with longevity and a lower incidence of chronic diseases, particularly coronary heart disease.
Cardioprotective effects of OO consumption have been widely related with improved lipoprotein
profile, endothelial function and inflammation, linked to health claims of oleic acid and phenolic
content of OO. With cardiovascular disease being a leading cause of death worldwide, a review
of the potential mechanisms underpinning the impact of OO in the prevention of disease is
warranted.
The current body of evidence relies on mechanistic studies involving animal and cell-based
models, epidemiological studies of OO intake and risk factor, small and large scale human
interventions, and the emerging use of novel biomarker techniques associated with disease risk.
This review critically appraises the available evidence to date, with particular focus on emerging
novel biomarkers for disease risk assessment. New perspectives on OO research are outlined,
especially those with scope to clarify key mechanisms by which OO consumption exerts health
benefits.

Silva et al 2015 New perspectives on bioactivity of olive oil
3
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
1. Relevance of the Mediterranean diet and olive oil to health
The olive tree, Olea europaea L., is one of the oldest agricultural tree crops and provides
diversified products for human consumption such as table olives and olive oil (OO)(1). The
analytical parameters to ascertain OO quality and classify OOs are defined by European Union
(EU) regulations(2). Oils obtained only by mechanical extraction are virgin olive oils (VOOs) and
further quality assessment can lead to a classification as extra virgin olive oil (EVOO)(3).
OO is the primary source of fat in the Mediterranean diet and has been associated with longevity
and a lower incidence of chronic diseases, particularly coronary heart disease (CHD)(4-7). OO
consumption is also associated with decreased rates of cancer, diabetes and neurodegenerative
diseases(8) as well as body weight reduction and obesity prevention(9, 10). The epidemiological
evidence underpinning the relevance of the Mediterranean diet to health is strong with over
seventeen studies including 2300 volunteers confirming that a Mediterranean diet decreases
inflammation and improves endothelial function(11), and a meta-analysis of thirty-two cohort
studies (> 800,000 subjects) indicating that there is an inverse correlation between OO intake and
coronary heart disease(12).
Olive oil bioactive components
The major components of OO are glycerols (saponifiable fraction) which represent more than
98% of of the total oil weight and are mainly triglyceride esters of oleic acid (55 to 83%),
palmitic acid (7.5 to 20%), linoleic acid (3.5 to 21%) and other fatty acids such as stearic acid
(0.5 to 5%)(13). Minor components (the unsaponifiable fraction) include aliphatic and triterpenic
alcohols, sterols, hydrocarbons as squalene, volatile compounds, tocopherols, carotenes,
chlorophyll and phenolic compounds(13-15).
Special attention has been given to the phenolic compounds only found in VOO and EVOO. The
agronomic and technological aspects of OO production have an impact on the concentration of
phenolic compounds, as does the pedoclimatic conditions and agronomic techniques
(e.g.: irrigation)(4, 14). The main classes of phenolic compounds present in VOO are phenolic
acids, phenolic alcohols (hydroxytyrosol and tyrosol), flavonoids, lignans and secoiridoids,
Table 1.
Oleuropein and ligstroside, the most significant secoiridoids in Olea europaea L., are esters of
elenolic acid glucoside with hydroxytyrosol and tyrosol, respectively. During the mechanical

Silva et al 2015 New perspectives on bioactivity of olive oil
4
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
extraction of the oil, fruit endogenous β-glucosidases(14, 16) are released leading to the secoiridoid
aglycones formation, accounting for more than 50% of the phenolic content of the oil(17, 18). The
most abundant secoiridoids of VOO are the oleuropein and ligstroside aglycons and dialdehydic
forms of deacetoxy of oleuropein and ligstroside aglycons(14) also named oleacein and
oleocanthal, respectively(19).
Phenolic compounds bioavailability and bioactivity
Once OO has been ingested, it produces a micellar solution composed of a lipid and an aqueous
phase. Chemical hydrolysis of secoiridoids can take place in the acidic medium of the
stomach(20) or in alkaline conditions in the small intestine(21, 22) leading to an increase of free
phenolic alcohols released into the aqueous phase. As a result OO phenolic compounds are
further absorbed in the small intestine(23). Measuring the bioavailability of these compounds in
plasma and urine reveals that OO phenolics undergo a conjugation process of methylation,
glucuronidation and to a lesser extent sulfation indicating that there is phase 2 metabolism
involved during the absorption of these compounds.
When assessing the chemical and in vitro biological antioxidant activities of these compounds, it
is the glucuronides conjugates of hydroxytyrosol and tyrosol that must be assessed. These were
tested in the range 0.01–10 μM against the radical 1,1-diphenyl-2-picrylhydrazyl (DPPH). None
of the glucuronides displayed significant antioxidant activities at the concentrations tested,
whereas the parent aglycones did display antioxidant activity at these concentrations(24). This
conflicts with the results of others(25) with differences attributed to the fact that in one study
reference standard material(24) was used and in the other the glucuronide conjugates were
extracted from urine samples(25), and likely contained inpurities that had antioxidant activity.
Hydroxytyrosol metabolites might act as "sinks" of hydroxytyrosol that could be locally released
in the cells after enzymatic hydrolysis(26), therby explaining the proposed hydroxytyrosol
biological effects observed in vivo. Moreover, in situ deconjugation of hydroxytyrosol
metabolites (into their free form) in red blood cells was observed in rats after oral administration
of an OO phenolic extract obtained from olive cake (1.5 g/kg body weight, equivalent to 34.4 mg
of hydroxytyrosol and derivatives), highlighting a potential protective mechanism against cell
oxidative damage(27).

Silva et al 2015 New perspectives on bioactivity of olive oil
5
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
Secoiridoids that are not absorbed in the small intestine are degraded by the colonic microbiota
with oleuropein producing hydroxytyrosol as the major product (20). In vitro colonic metabolism
was evaluated on tyrosol, hydroxytyrosol, hydroxytyrosol acetate and oleuropein showing an
increase in phenolic acids, stability of hydroxytyrosol and tyrosol and degradation of
hydroxytyrosol acetate and oleuropein mainly to hydroxytyrosol(28). In order to evaluate OO
phenolic metabolites produced from colonic fermentation, faecal samples were analysed before
and after mid-term consumption of phenol-rich OO(28). A significant increase in hydroxytyrosol
concentration (p < 0.05) was observed after phenol-rich OO intake. Although absorption of OO
phenolic compounds mainly occurr in the small intestine a small proportion of hydroxytyrosol
and its derivatives still pass into the large intestine(23). This highlights the need to study the
impact of OO phenolics in the colon, either with gut microbiota interaction or local activity due
to its antioxidant and anti-inflammatory properties.
2. Olive oil and inflammation
Inflammation involves a complex cascade of events partly related with the production of an
excess of free radicals due to internal or environmental stress(29). The inflammation process
triggers signaling molecules such as nuclear factor-kappa-B (NF-kB), which up-regulates the
production of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α)(30) inducible
NO synthase (iNOS), cyclooxygenase-2 (COX-2), and interleukin-1beta (IL-1β)(29).
A number of phenolic compounds present in OO have anti- inflammatory properties, including
oleocanthal, a secoiridoid (dose-dependent inhibition of COX-1 and COX-2 activities, similar to
the anti-inflammatory drug ibuprofen(31)). However, to achieve comparable effect to the
recommended daily dose of ibuprofen, 500 g of EVOO would need to be consumed(32, 33) making
the dose/effect relationship outwith any (acute) inflammatory benefits due to typical OO
consumption.
Chronic inflammation
Rheumatoid arthritis (RA) is a major inflammatory, autoimmune, disease characterized by
chronic joint inflammation(34, 35). Hydroxytyrosol has been studied for its anti-inflammatory
effects in a RA animal model. We reported that it provided beneficial effects in the evolution of
the disease(36), with 0.5 and 5 mg/kg doses in rats, after gavage administration, using refined OO
as vehicle (human-equivalent of 4.9 and 49 mg/day, respectively, for a 60 kg adult), Figure 1.

Silva et al 2015 New perspectives on bioactivity of olive oil
6
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
Significant effects, on paw edema reduction, were observed for a human-equivalent dose of
49 mg/day, a dose 10 times higher than the approved Food and Drug Administration and
European Food Safety Authority (EFSA) dose for phenolic compounds in relation to protection
of lipid oxidation(37). The same hydroxytyrosol dose was effective on colitis, another chronic
inflammatory disease(38). This dose would only be achievable through nutraceutical
supplementation of OO with hydroxytyrosol, and the use of this functional food on a daily basis.
To further evaluate the anti-inflammatory mechanisms involved with hydroxytyrosol, we studied
COX-2 and iNOS expression(36). The treatment at 5 mg/kg dose significantly decreased
histological damage, COX-2 and iNOS expression (p<0.001 vs. positive control), markedly
reduced the degree of bone resorption, soft tissue swelling and osteophyte formation, improving
articular function in treated animals. Moreover at the same dose there was a significant decrease
(p<0.005 vs. positive control and refined OO) in TNF-α serum levels. These results are in line
with others that reported benefits on RA, in animal models, after oral administration of an EVOO
extract(39), intraperitoneal administration of oleuropein aglycone(40) or polyphenol supplemented
VOOs diets(41). The reports highlight effects on RA of OO phenolic compounds either
administered as isolated compounds or as an extract. However, doses comparison between
animal studies have to to take in consideration not only differences in species (rats vs. mice) but
also routes of administration. Compared to intraperitoneal administration, an oral dose has an
extra pass through the liver with consequent metabolism through the first-pass effect.
Acute inflammation
Acute inflammation has been commonly induced using carrageenan in animals in order to
evaluate the effects of non steroid anti-inflammatory drugs (NSAIDs)(42). We studied the effect
of hydroxytyrosol-supplemented OO on acute inflammation, induced by carrageenan in rats, at
0.5 and 5 mg/kg(36) dose, after gavage administration which occurred 30 min before the challenge
with carrageenan. Both doses significantly reduced paw edema (p<0.001 vs. positive control)
with the lowest effective dose being achievable through OO daily intake. Previous studies in
rats(43) also showed inhibition of carrageenan - acute inflammation of an aqueous hydroxytyrosol
formulation (HT-20, 22% hydroxytyrosol), and significant effects were obtained at a 22 mg/kg
hydroxytyrosol dose. Differences in dose effect might be related to the administration vehicle
with ROO or OO being better vehicles than water.

Silva et al 2015 New perspectives on bioactivity of olive oil
7
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
Vehicles of administration of OO phenolic compounds on animal and human studies
Using OO as the intake vehicle can promote absorption of hydroxytyrosol: the corresponding
bioavailability of hydroxytyrosol in rats for aqueous and OO solutions were reported as 75 and
99%(44), respectively. When a supplement containing hydroxytyrosol as a single oral
dose (2.5 mg/kg) was fed to humans, the bioavailability was below 10%(45), while previous
studies showed higher bioavailability for hydroxytyrosol supplementation in lipid vehicles(46).
The addition of hydroxytyrosol to low fat yogurt and administered to humans was also associated
with a lower excretion of hydroxytyrosol when compared with OO(46). As OO phenolic
compounds are mainly absorbed in the small intestine(23) the increase of hydroxytyrosol
bioavailability, in OO, might be related to the rate of gastric emptying(45) and slow release of
hydroxytyrosol from the oil matrix(45, 47). The presence of other antioxidants in OO might prevent
breakdown of hydroxytyrosol before absorption in the gastrointestinal tract(44).
Although there are a number of anti-inflammatory effects for OO phenolic compounds, most
cannot be achieved via normal dietary exposure to OO. This has led to development of enriched
products with natural OO phenolic compounds. OO by-products such as olive mill wastewater(48)
and olive pomace(49, 50) are potential sources of natural bioactives which could be used to
supplement OO. The development of new OO products such as pomace OO or refined OO
enriched in natural bioactives opens new perspectives in the field.
3. Cardioprotection of olive oil
Most of the interventional studies focusing on the benefit of VOO intake on cardiovascular
disease have investigated the effect of phenolic compounds on the prevention of oxidation of
low-density (LDL) and high-density (HDL) lipoproteins(51-58), two risk markers of cardiovascular
disease. A number of trials have also focused on cardioprotection against inflammation(59)
mainly on antioxidant activity and inflammatory mediators.
Impact of olive oil constituents on lipoproteins and atherosclerosis
Fat content
LDL particles carry about two-thirds of plasma cholesterol and can infiltrate the arterial wall
attracting macrophages, smooth muscle cells, and endothelial cells(60) thus driving atherosclerosis.

Silva et al 2015 New perspectives on bioactivity of olive oil
8
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
LDL particle size is influenced by type and amount of dietary fat consumed(61): Low-fat diets
lead to a decrease in the size of LDL particles compared to high-fat diets(62). The type of fat
ingested is also important: LDL particles are larger with high-monounsaturated fatty acid diets
(such as those based on OO), compared to diets with a high polyunsaturated fatty acids intake,
where LDL particles are smaller(63). LDL particle size is especially relevant, since small size
particle are more prone to oxidation and can better enter into the arterial wall when compared
with larger LDL particles(64). Conversely, HDL particles are antiatherogenic, as their primarily
role is to deliver cholesterol to the liver to be metabolized and excreted or reused. HDL may also
be able to dislodge cholesterol molecules from atheromas in arterial walls(60). It has been
reported in patients with peripheral vascular disease(65, 66), that LDL particles are less susceptible
to oxidation when the diet is enriched in VOO monounsaturated fatty acids, compared to the
polyunsaturated fatty acids of sunflower oil enriched diets. Moreover when compared to
saturated fatty acids intake, OO oleic acid reduces the level of LDL-cholesterol(57, 58).
The health benefits associated with monounsaturated fat content in OO were recognised by the
United States Food and Drug Administration (FDA) in 2004, highligthing “the benefits on the
risk of coronary heart disease of eating about two tablespoons (23 g) of OO daily”(67). Health
benefits were related with a decrease of total and LDL cholesterol in serum(67), diet improvement
of endothelial dysfunction(68), coagulation activity(69) and reduced LDL susceptibility to
oxidation(66).
Phenolic content
Antioxidants that can prevent lipid peroxidation, such as phenolic compounds, could play an
important role in preventing oxidative modification of LDL(4), with the oxidative process an
initiating factor for atherosclerotic plaques(70). Once monocytes differentiate in macrophages on
the endothelium they scavenge oxidized LDL (ox-LDL), then becoming foam cells, leading to
plaque formation(5).
The Effect of Olive Oil on Oxidative Damage in European Populations (EUROLIVE) study was
a cross-over fat replacement intervention(52), using OOs with different phenolic content in
healthy male volunteers. Its findings led to the current EFSA recommendation (Opinion of the
Scientific Committee/Scientific Panel, EFSA Journal(37, 71, 72)). A linear increase in HDL-
cholesterol levels after 3 weeks was observed after low-, medium-, and high-polyphenol OO
consumption: mean change from preintervention, 0.02 mmol/L (95% CI, 0.00 to 0.05 mmol/L),

Silva et al 2015 New perspectives on bioactivity of olive oil
9
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
0.03 mmol/L (95% CI, 0.00 to 0.05 mmol/L) , and 0.04 mmol/L (95% CI, 0.02 to 0.06 mmol/L),
respectively. Total cholesterol:HDL cholesterol ratio decreased linearly with the phenolic
content of the OO. Triglyceride levels decreased by an average of 0.05 mmol/L for all OOs(52).
Mean changes from preintervention for ox-LDL levels were 1.21 U/L (95% CI, -0.8 to 3.6 U/L),
-1.48 U/L(95% CI, -3.6 to 0.6 U/L) and -3.21 U/L (95% CI, -5.1 to -0.8 U/L) for the low-,
medium-, and high-polyphenol OO, respectively, showing a dose-dependent relation with VOO
phenolic content(52). The EFSA confirmed a cause effect relationship between consumption of
OO phenolics (standardized by the content of hydroxytyrosol and its derivatives) and protection
of LDL cholesterol particles against oxidative damage. To support the EFSA health claim, 5 mg
of hydroxytyrosol and its derivatives should be consumed daily in 20 g OO(37), but
concentrations in some OOs may be too low to achieve this target in the context of a balanced
diet. Moreover, the EFSA Panel commented study design limitations as most human
interventions with OO have been conducted in more homogeneous male populations(71) and not
in general population.
The contribution of OO phenolics toward cardiovascular health benefits has been challenged
with inconsistent results reported for ex vivo resistance of LDL to oxidation(73, 74). Seven human
intervention studies with OO were compared for impact of phenolics on ox-LDL, with no effect
seen in five of them(73), possibly explained by artifacts generated during LDL isolation.
Since the approval of the EFSA claim, both terminology and analytical methodology supporting
the dose calculation of hydroxytyrosol and derivatives have been appraised. Mastralexi et al.(75)
commented on the weaknesses of the claim terminology namely the term “olive oil polyphenols”
is not entirely clear and accurate as “olive oil” is a generic term for the type of oil, and the basic
structure of OO phenolic compounds do not coincide with a “polyphenolic” structure;
accordingly “virgin olive oil bioactive phenols” is a more appropriate term. Others also
commented about the lack of robust and reliable methods for quantifying phenolic compounds in
OO. A simple and robust method for routine analysis of hydroxytyrosol and tyrosol was
proposed(75, 76) based on hydrolysis of the polar fraction of OO. This was followed by
development and validation of a 1H NMR method enabling direct measurement of tyrosol and
hydroxytyrosol derivatives, as well as oleocanthal and oleacein in OO, overcoming analytical
issues such as chromatographic peak broadening(19).

Silva et al 2015 New perspectives on bioactivity of olive oil
10
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
Cardioprotective mechanisms of oleic acid
OO intake has been related with a decrease on blood pressure with oleic acid regarded as being a
major contributor to this effect, as evidenced in animal models(77). Chronic oral administration of
VOO (rich in oleic acid), triolein (a triacylglyceride with three oleic acid moieties) or oleic acid
over 14 days significantly reduced systolic blood pressure in rats (-26 ± 4 for VOO and -21 ± 3
mm Hg for triolein, p<0.001, and -17 ± 1.9 mm Hg for oleic acid p<0.05) when compared to the
control group that received water. Similarly acute (2 h) treatments with either VOO or triolein
also significantly reduced systolic blood pressure when compared to the control group
(-20 ± 0 mm Hg, p < 0.001, and -14 ± 2 mm Hg, respectively, p < 0.05) with oleic acid again
significantly reducing systolic blood pressure (-13.0 ± 0.3 mm Hg; p < 0.001). In contrast,
chronic treatment with the trans-monounsaturated fatty acid elaidic (18:1n-9) or the saturated
fatty acid stearic acid (18:0) did not significantly affect blood pressure. Results show that
saturation and cis/trans double bond arrangement are implicated with the cardioprotective effect
of the long chain fatty acid in this animal model at high dose levels(77). Similar significant results
were obtained after VOO and oleic acid intake in an animal model of hypertension using
spontaneously hypertensive rats(77).
The molecular mechanisms were evaluated by measuring signaling proteins involved in the
control of blood pressure in the aorta. OO intake increases oleic acid levels in membranes, which
regulate membrane lipid structure and impact on G protein-mediated signaling, causing a
reduction in blood pressure(78). Unlike its analogues elaidic and stearic acid, oleic acid, due to its
cis-18:1n-9 structure, regulates cellular membrane lipid structure and the α2 receptor system
involved in the control of blood pressure (α2A/D - adrenoreceptor/G protein/adenylyl cyclase-
cAMP/PKA) as demonstrated in vitro(78) and in vivo(77). Oleic acid can also contribute to heart
health via intramyocardial triglyceride turnover(79), which is reduced in pressure-overloaded
failing hearts. In this situation oleate (derivative of oleic acid) upregulated triglyceride dynamics
when compared to palmitate (derivative of palmitic acid and major saturated fatty acid of palm
oil). This result underscores the importance of the intracellular lipid storage type on nuclear
receptor signaling and contractility(79) in diseased hearts.
An important driver of vasorelaxation is nitric oxide, a free radical which readily reacts with fats
and proteins. Nitro-fatty acids are mediators of cardiovascular signaling actions(80) as these
compounds relax blood vessels, attenuate platelet activation, and reduce inflammation(81, 82).

Silva et al 2015 New perspectives on bioactivity of olive oil
11
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
Both oleic acid and linoleic acid are unsaturated fatty acids that after reaction with nitrite may
form nitro-fatty acids. Nitro-oleic acid mediated antihypertensive signaling actions were shown
in a mouse model(83). The mechanism was attributed to the inhibition of soluble epoxide
hydrolase by nitro-fatty acids, thus lowering blood pressure in an angiotensin II-induced
hypertension(83). It is however unclear how the extent of nitrite in the human diet may contribute
to nitration of dietary fat, and the physiological relevance of this finding.
Role of phenolic compounds on endothelium protection
Oxidative stress and reactive oxygen species (ROS) have been implicated in endothelial damage,
progression to atherosclerosis, injury in sustained myocardial infarction and ischemia
reperfusion(70, 84-86). Monocytes and macrophages are critical cells that are involved in
atherosclerosis. These cells produce proinflammatory cytokines, such as IL-1β, TNF-α and
C-reactive protein (CRP), which induce the expression of adhesion molecules like intercellular
adhesion molecule-1 (ICAM-1), vascular-cell adhesion molecule-1 (VCAM-1), and E-selectin(87).
Meanwhile, oxidative stress through ROS production promotes the expression of the adhesion
molecules on the endothelium(88).
Expression of adhesion molecules attracts circulating monocytes inducing their adherence to the
endothelium. OO phenolic compounds have been shown to act on endothelium protection as
evidenced in in vitro assays with typical OO phenolic compounds and less on in vivo circulating
metabolites. OO phenolic extract, oleuropein aglycone or homovanillic alcohol (metabolite of
hydroxytyrosol) had inhibitory effects on VCAM-1, ICAM-1 and E-selectin surface expression
in human umbilical vascular endothelial cells, using TNF-α as pro-inflammatory stimulus(89).
Endothelium dysfunction refers to an impairment of endothelium-dependent vasorelaxation
caused by a loss of NO bioactivity in the vessel wall. In animal models with rats oral
hydroxytyrosol administration was tested on NO production and platetet function(90). Results
showed that hydroxytyrosol administration (100 mg/kg/day) increased vascular NO production
by up to 34.2% (p < 0.01) and inhibited platelet aggregation for 50% inhibitory dose of
48.25 mg/day for hydroxytyrosol (p<0.01) when compared to control group (treated with
isotonic saline solution). Animal dose translation to humans allowed us to conclude that the
effective hydroxytyrosol doses tested would be above the expected intake through OO daily. The
reported benefits would only be achievable through nutraceutical supplementation.

Silva et al 2015 New perspectives on bioactivity of olive oil
12
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
Endothelium repair: matrix metalloproteinases and olive oil
Matrix metalloproteinases (MMPs) play a role in endothelium repair. Macrophages resident in
human and experimental atherosclerosis co-localize with and release active MMPs including the
gelatinase MMP-9, which is specialized in the digestion of basement membrane collagens and
elastin, and is implicated in atherogenesis, unstable coronary syndromes, and in aortic
aneurysms(91). Accumulating evidence points to the MMPs as major molecular mediators of
arterial diseases(91). Collagens, types 1 and 3, are the main proteins in arterial walls being also
present in the thickened intima of atherosclerotic lesions(92, 93). Fragments of collagens found in
urine are present as a result of proteolytic activity in arterial walls and other vascular structures.
Collagen type 1 or 3 fragments were up-regulated in urine in coronary artery disease (CAD)
patients(94). Increase in collagen degradation is related with an increase on collagenases
circulation, such as MMP-9, as shown in patients with CAD(95).
In an in vitro study hydroxytyrosol (1-10 μM) reduced MMP-9 (IC50 = 10 μmol/L, p< 0.05) and
COX-2 induction in activated human monocytes, with phorbol myristate acetate (PMA)(96).
These effects were mediated by inhibition of transcription factor NF-κB and protein kinase C
(PKC) α and PKCβ1 activation(96). Results are in line with previous in vitro reports that showed
inhibition of MMP-9 on endothelial cells by OO phenolics namely hydroxytyrosol in PMA
induced cells(97), and oleuropein aglycone in TNF-α induced cells by acting on NF-κB(88). No
hydroxytyrosol activity on MMP-9 was found in TNF-α induced cells(88).
The discriminatory polypetides that increase in CAD includes collagen type 1 and 3 fragments
with a C-terminal GxPGP motif (98). Increase on these polypeptides would come from a protease
decrease activity possibly related with chemical change of the substrate (e.g.: oxidative damage)
thus inhibiting it acting at a specific site, or a decrease in circulating levels by lack of enzyme
activation. MMP-2 is secreted in an inactive form (pro MMP-2) and several factors can promote
its activation such as plasmin(99) and thrombin(100). Other mechanisms that involve proteinases or
oxidative stress can also activate MMP-2(101). Therefore antioxidants, as phenolic compounds,
might have a role on MMP-2 activation and published data indicate phenolic compounds from
red wine(102) and green tea(103) as acting on prevention of thrombin-induced activation of MMP-2
in vascular smooth cells.
We evaluated the impact of a 6-week OO supplementation in healthy adults on urinary proteomic
biomarkers of coronary artery disease (CAD) in a randomized, parallel, controlled, double-blind

Silva et al 2015 New perspectives on bioactivity of olive oil
13
Manuscript published in Proceedings of Nutrition Society, DOI:10.1017/S0029665115002323
study(104). This study was the first to describe the significant impact of daily OO supplementation
on highly specific disease biomarkers for CAD. Analysis of urinary proteomic profiles at
baseline and endpoint enabled the identification of 12 sequenced peptides that were significantly
regulated toward healthy scoring. Eight of them included four collagen α-1(I) chain, one α-2 (1)
chain, one α-2(V) chain, and one α-2(VI) chain fragments. Changes in circulating concentrations
of collagenases may mediate these changes in the urinary fingerprint. Therefore with more data
or in future intervention studies with OO it would be interesting to link urinary fragments to the
proteases involved in their generation. This predictive analysis would enable looking at the
peptide cleavage sites studying the MMPs up or downregulated with OO intervention.
The majority of studies of dietary intake of proposed bioactive foods asses the activities of these
foods based on the major risk factors of cardiovascular disease. However marker such as
lipoprotein profile, blood pressure, endothelial function, inflammation and oxidative stress have
no direct link to the disease itself but are merely associated with it. There is a great need for more
biomarkers that appear as a direct result of the disease itself(57, 61).

Silva et al 2015 New perspectives on bioactivity of olive oil
14
4. Proteomics biomarkers as a mechanistic approach to explain olive oil health effects
The systems biology approach (encompassing genomics, transcriptomics, proteomics and
metabolomics using urine, blood or saliva) could provide a greater understanding of disease
development, treatment efficacy and evaluation of the influence of food bioactive
compounds (33, 105). There is a need for biomarkers of practical value for clinical intervention,
allowing disease risk prediction and more importantly early diagnosis. Accuracy, reproducibility,
availability, feasibility of implementation into the clinical settings, sensitivity and specificity are
additional characteristics to be fulfilled, and panels of biomarkers are gaining acceptance instead
of individual molecules(106), as single biomarkers are often not available and lack the ability to
adequately describe complex diseases(107). Candidate biomarkers should be carefully validated in
a wide and different cohort of samples from those used in the discovery phase as often
overfitting of the biomarker model has occurred(108) .
The proteome, corresponding to a set of expressed proteins, informs the current “status” of an
organism, constantly changing according to endogenous and exogenous factors(107). Proteins are
widely used in different clinical tests for both diagnosis and prognosis of diseases and to follow
their evolutions(92). They can be used to measure the extent of inflammation, calcification, and
the development of plaques on the arteries. Understanding what causes plaque rupture is of great
importance. As previously mentioned, MMPs could have a key role in this process(109). The
discovery of proteomic biomarkers may be useful in understanding the molecular mechanisms
involved in the onset and progression of other vascular diseases(110). Plasma, serum and urine are
the most commonly used biological matrices in cardiovascular research, due to their perceived
clinical relevance as a source of potential biomarkers(92). However proteomic studies have also
been carried out on vascular tissues (arteries), artery layers, cells looking at proteomes and
secretomes, exosomes, lipoproteins, and metabolites(92). Although sampling the tissue may seem
an obvious method there are a number of difficulties, especially where the need for a biopsy
would be required(111). Recent advances in extraction processes and LC-MS/MS analysis has
allowed the quantitative analysis of tissue samples in vascular research to be carried
out(112, 113).
Urine, as a sample source is now recognized as the source of choice for proteomic biomarker
investigations. It has a number of advantages such as being noninvasive and can be collected by
untrained personnel. Urine is produced by renal filtration of the plasma and approximately 70%

Silva et al 2015 New perspectives on bioactivity of olive oil
15
of proteins in the normal human urinary proteome are of kidney origin, whereas the remaining
30% are derived from plasma proteins (114, 115). It has high stability due to absence of proteolytic
agents and the low dynamic range of analyte concentration facilitates the detection and
quantification of peptides(107, 116).
Using capillary electrophoresis coupled with mass spectrometry (CE-MS)(117) urinary biomarker
classifiers for the diagnosis of diseases like chronic kidney disease(118), acute kidney injury(119),
stroke(120), and coronary artery diseases(98), were already identified, allowing classification of
case versus control groups with good accuracy(121).
Urinary peptides and protein fragments are the end products of proteolytic processes. The
different pattern of urinary excretion of peptides when comparing controls and disease patients
might indicate their role in the pathophysiology of disease. Therefore changes in the normal
urine "fingerprint" (e.g.: presence of collagen fragments) can be used as biomarkers of disease.
Besides collagens, common blood proteins (e.g., alpha-1-antitrypsin, hemoglobin, serum
albumin, and fibrinogen), and uromodulin were also identified(122) in urine which provides
additional proof of the suitability of this sample source for proteomic biomarker studies out with
the kidney and urinary tract. Collagens are the most abundant peptides sequenced so far in the
CAD biomarker (66% of all peptides)(98), with atherosclerosis associated with an increased
synthesis of several extracellular matrix components, including collagen types 1 and 3, elastin,
and several proteoglycans(123). Changes in the circulating levels of collagenases may mediate
these changes in peptides represented in the fingerprint, as reported in coronary
atherosclerosis(94), and chronic kidney disease(122).
The progress in urinary proteomics and the use of multiple biomarker classifiers opens the
possibility of establishing new tools adapted to different clinical needs(124), enabling direct
monitoring of disease overcoming limitations of indirect measurements.
Proteomic in vitro studies on olive oil phenolic compounds
Proteomics has been applied in a number of studies of OO phenolic compounds on
cardiovascular health using animal and in vitro studies. The in vitro effects of alperujo extract, an
OO production waste product containing phenolic compounds present in olive fruits, were
studied on platelet aggregation and changes in the platelet proteome(125). Nine proteins were
differentially regulated by the alperujo extract upon platelet aggregation underlying the anti-

Silva et al 2015 New perspectives on bioactivity of olive oil
16
platelet effects of the extract. However, like a number of previously mentioned in vitro studies,
the effective concentrations (40-500 mg/L) were far above the physiologically concentrations
achievable by dietary intake.
The effects of EVOOs, with low and high in phenolic content, were evaluated in the hepatic
proteome in Apoe-/- mice that spontaneously develop atherosclerosis(126). For 10 weeks the mice
were fed with a high fat high cholesterol diet supplemented with 0.15% (w/w) cholesterol and
either 20% (w/w) low phenolic EVOO or 20% (w/w) high phenolic EVOO versus a control
group fed with 0.15% (w/w) cholesterol and 20% (w/w) palm oil. Within this work a range of
hepatic antioxidant enzymes differentially regulated by OO(126) were identified. The authors
concluded that the up-regulation of a large array of antioxidant enzymes might explain anti-
atherogenic mechanisms of EVOOs(126). Again the dose level was above what could be achieved
through dietary intake and translation from an animal model to human has also to be considered.
Urinary proteomics biomarkers, olive oil and cardiovascular disease
Atherosclerosis is a process of chronic inflammation, characterized by the accumulation of
lipids, cells, and fibrous elements in medium and large arteries(92). The extent of
inflammation, proteolysis, calcification, and neovascularization influences the development of
advanced lesions (atheroma plaques) on the arteries(92).
Classical risk factors in atherosclerosis (hypertension, LDL-cholesterol, C-reactive protein,
aging, smoking, male gender, among others) do not actually measure disease initiation or
progression. As such, they cannot be used directly to identify individuals who have developed
atherosclerosis and prevent a fatal event(92, 127). Other, more recent markers that indicate changes
in vascular structure can still only be detected once cardiovascular disease has progressed to an
advanced stage where drug or surgical intervention is required(128).
The analysis of urine samples from diseased and healthy individuals has been used to establish a
database of naturally occurring urinary peptides, making a basis for the definition and validation
of biomarkers for diagnosis/prognosis/monitoring of a wide range of diseases using proteomic
biomarker patterns(122), such as CAD(94), emphasizing that non-invasive proteomics analysis
could become a valuable addition to assess cardiovascular disease alongside to other biomarkers
which are indicators of cardiovascular risk.

Silva et al 2015 New perspectives on bioactivity of olive oil
17
The first time that urinary proteomics was applied to assess cardiovascular health improvements
of OO consumption in humans, was in a randomized, parallel, controlled, double-blind study
designed to evaluate the impact of a 6 week OO supplementation in healthy adults on urinary
proteomic biomarkers of CAD(104). The impact of the supplementation with OO was also studied
on urinary proteomic biomarkers of chronic kidney disease (CKD), and diabetes.
The increase or decrease in the concentration of the peptides in the biomarker determines the
scoring value of each disease biomarker. The CAD proteomic biomarker developed for clinical
diagnosis produces a CAD scoring system from 1 (CAD case) to -1 (healthy artery). A scoring of
disease absence, presence and severity is provided, based on the concentration of a group (panel)
of urinary peptides measured by CE-MS, allowing monitoring of progression and/or effect of
treatment(129, 130). In this study, self-reported healthy participants were randomly allocated to
supplementation with a daily dose of OO either low or high in phenolic compounds. For 6
weeks, they consumed a daily dose of 20 mL OO (not heated or cooked) as a supplement (no
specific time during the day, single intake, equivalent to 6 mg of hydroxytyrosol and derivatives
for the high phenolic OO), in line with the EFSA and FDA recommendations.The impact of
supplementation with OO was evaluated on urinary proteomic biomarkers of CAD with
biomarkers being measured at baseline and 3 and 6 weeks. Consumption of both OOs
significantly improved the proteomic CAD score at endpoint compared with baseline, moving
the CAD biomarker pattern in a healthy profile direction, Table 2. No differences were observed
for CKD or diabetes proteomic biomarkers, Table 2.
In a placebo-controlled intervention, Irbesartan (angiotensin II receptor antagonist used for the
treatment of hypertension) taken at 300 mg per day over 2 years in hypertensive type 2 diabetes
patients, using the CAD 238 biomarker panel, led to a 0.35 point reduction in the CAD score for
the drug-controlled group(98), which saw a significant reduction in incidents of CAD in this
group. In the nutritional intervention(104) the CAD score change in the intervention was
significant for both OOs tested, using the same CAD 238 biomarker, leading to a similar degree
of change as observed for irbersartan over a 6 week period. This evidence highlights the
importance of the CAD biomarker as a tool for nutrition and health intervention studies. This
type of urinary biomarker enabled the measurement of health effects induced by a change in diet
that could not be detected by monitoring the conventional risk markers of CAD such as plasma
triacylglycerols, oxidized LDL, and LDL cholesterol. The overall change in CAD score in a

Silva et al 2015 New perspectives on bioactivity of olive oil
18
short period of time is more likely due to OO major components, such as fatty acids. However
the role of other OO minor components other than phenolic compounds should also be taken into
account. Squalene, a polyunsaturated triterpene which makes up 60–75% of the unsaponifiable
fraction of OO(131), reduced atherosclerotic lesion size in male mice(132) and further investigation
is needed to clarify its role on cardiovascular disease.
Our results emphasize further the potential role of nutrition in the prevention or delay of
cardiovascular disease and offer new perspectives on OO applications. These results are highly
translatable to guidelines for nutritional recommendations. The biomarkers were originally
developed to detect early signs of diseases in clinical setting and to inform clinician as to the
effectiveness of treatment. However, the technology also provides a sensitive tool for the
assessment of potential bioactive foods in cardiovascular health, chronic kidney disease and
diabetes, with a range of additional tests under development. Further testing of reportedly
bioactive foods can now be carried out which will allow better nutritional health advice to be
advanced and could also lead to better food labeling so that the public can make informed
choices on their food purchases.

Silva et al 2015 New perspectives on bioactivity of olive oil
19
5. Exploring olive oil health benefits: perspectives 1
Although strong evidence from heritability is related with cardiovascular disease many forms of heart 2
disease are not genome associated(133). The epigenome is a possible link between genetics and 3
environment(133) which includes impact of food components/diet. Omics techniques (genomics, 4
transcriptomics, proteomics, epigenomics, metabolomics) have the potential, when integrated, to paint 5
a comprehensive picture of the contribution of diet toward the modulation of disease risk(141). Some 6
trials have shown the impact of OO on down-regulation of atherosclerosis-related genes(134, 135). The 7
effect of Mediterranean Diet was studied on urinary metabolome(136) and related to compounds of the 8
metabolism of carbohydrates, creatine, creatinine, amino acids, lipids and microbial cometabolites. 9
Phenolic compounds can interact with cellular signaling cascades regulating the activity of 10
transcription factors with impact on gene expression. For instance, phenolic compounds have shown to 11
affect the expression of microRNAs (miRNA)(137). miRNAs are small, noncoding RNAs implicated in 12
the regulation of gene expression that control both physiological and pathological processes, influenced 13
by external factors as diet components(138). Most of the studies reported in this field are in vitro and 14
more in vivo studies are needed to clarify miRNA targets of dietary phenolic compounds(138). 15
Interactions between genes and the bioactive components present in OO studied by nutrigenomics may 16
help to explain its health benefits(139). In this sense, besides their antioxidant and anti-inflammatory 17
capacities, OO phenolic compounds are able to modify gene expression coding in a protective mode for 18
proteins participating in the cellular mechanisms involved in oxidative stress resistance, inflammation 19
or lipid metabolism amongst others(140). 20
Glycation, a non-enzymatic reaction between reducing sugars and proteins, is a proteome wide 21
phenomenon, mainly observed in diabetes due to hyperglycemia(141), but also relevant to end organ 22
damage, disease pathogenesis and aging(142) and OO phenolic compounds have been reported as potent 23
inhibitors of the formation of advanced glycation end products(143). Our human intervention trial with 24
OO low or high in phenolics did not find a significant impact on plasma fructosamine levels(104). A key 25
factor may be the duration of the study (6 weeks) not being sufficient to detect changes in protein 26
modifications such as glycation, and may also be partly related to the quantity and quality of phenolic 27
compounds, which exert differential antioxidant and antiglycative activities depending on 28
structure(4, 144). Further studies should proceed in order to clarify anti-glycation properties of OO 29
phenolic compounds, given that glycation is a key driver for tissue damage and is present in all non-30
communicable disease scenarios. 31
32

Silva et al 2015 New perspectives on bioactivity of olive oil
20
6. Final Remarks 33
The reported health benefits of the Mediterranean diet and OO consumption may allow the 34
implementation of primary prevention programs of cardiovascular disease, based on nutritional 35
interventions. These interventions would have a particular relevance in non-regular OO consumers like 36
the Northern European populations. 37
Human intervention trials focusing on new outcomes related with proteomics and nutrigenomics are 38
needed to better clarify pathways/mechanisms by which oleic acid, phenolic compounds from OO or 39
even other components act on cardiovascular disease risk factors and affect the proteome. 40
41
7. Financial Support 42
QREN project Azeite+ Global nº 12228 and Ordem dos Farmacêuticos (Lisbon, Portugal). 43
44
8. Conflict of Interest 45
Conflict of interest: Thomas Koeck is employed at Mosaiques Diagnostics, the company that 46
developed the urinary proteomics for CE-MS technology for clinical application. No other authors 47
declare a conflict of interest. 48
49
50

Silva et al 2015 New perspectives on bioactivity of olive oil
21
Table 1 – Main classes of phenolic compounds in virgin olive oil
Phenolic acids
Phenolic alcohols
Flavonoids
Caffeic acid
Hydroxytyrosol
Tyrosol
Luteolin
Lignans
Secoiridoids
(+) - Pinoresinol
Oleuropein aglycone
(3,4-DHPEA-EA)
Ligstroside aglycone
(p-HPEA-EA)
Dialdehydic form of deacetoxy
oleuropein (3,4-DHPEA-EDA)
OH
OH
CH
CH
COOH

Silva et al 2015 New perspectives on bioactivity of olive oil
22
Table 2 Changes in scores of CAD, CKD and diabetes proteomic biomarkers at baseline, middle (3-weeks) and
end of intervention (6 weeks)1
Low phenolic olive oil (n = 34)
High phenolic olive oil (n = 28)
Score
Changes relative to baseline
Score
Changes relative tobaseline
CAD proteomic biomarker
baseline
-0.5 ± 0.2
-
-0.6 ± 0.4
-
3 weeks
-0.7 ± 0.3
-0.2 ± 0.3 (-0.3, -0.1)
-0.7 ± 0.3
-0.1 ± 0.4 (-0.3, 0.0)
6 weeks
-0.8 ± 0.3
-0.3 ± 0.2 (-0.4, -0.2)**
-0.8 ± 0.3
-0.2 ± 0.3 (-0.4, -0.1)*
CKD proteomic biomarker
baseline
-0.4 ± 0.2
-
-0.4 ± 0.3
-
3 weeks
-0.4 ± 0.2
0.0 ± 0.3 (-0.1, 0.1)
-0.4 ± 0.3
0.1 ± 0.3 (0.0, 0.2)
6 weeks
-0.4 ± 0.2
0.0 ± 0.3 (0.0, 0.1)
-0.4 ± 0.2
0.0 ± 0.3 (-0.1, 0.1)
Diabetes proteomic biomarker
baseline
1.3 ± 0.3
-
1.3 ± 0.3
-
3 weeks
1.3 ± 0.4
0.1 ± 0.4 (-0.1, 0.2)
1.3 ± 0.3
-0.1 ± 0.4 (-0.2, 0.1)
6 weeks
1.4 ± 0.4
0.1 ± 0.4 (0.0, 0.2)
1.2 ± 0.3
0.0 ± 0.4 (-0.2, 0.1)
1Values are means ± SDs; 95% CIs in parentheses. A repeated-measures ANOVA test was used with statistical significance at p < 0.05. ***Compared with
corresponding baseline value: *p < 0.005, **p < 0.001. There were no significant differences in changes between groups. CAD, coronary artery disease; CKD,
chronic kidney disease (adapted from Silva et al.(104)).

Silva et al 2015 New perspectives on bioactivity of olive oil
23
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
REFERENCES 16
17
1. Obied HK, Prenzler PD, Ryan D, Servili M, Taticchi A, Esposto S, et al. Biosynthesis and 18 biotransformations of phenol-conjugated oleosidic secoiridoids from Olea europaea L. Natural product 19 reports. 2008;25(6):1167-79. 20 2. European Comission, Official Journal of the European Union, 27.1.2011, Comission Regulation 21 (EC) No 61/2001 of 24 January 2011 22 3. European Comission, Official Journal of the European Union, 5.7.2008, Comission Regulation 23 (EC) No 640/2008 of 4 July 2008. 24 4. Tripoli E, Giammanco M, Tabacchi G, Di Majo D, Giammanco S, La Guardia M. The phenolic 25 compounds of olive oil: structure, biological activity and beneficial effects on human health. Nutrition 26 research reviews. 2005;18(1):98-112. 27 5. Covas MI. Olive oil and the cardiovascular system. Pharmacological research : the official 28 journal of the Italian Pharmacological Society. 2007;55(3):175-86. 29 6. Lopez-Miranda J, Perez-Jimenez F, Ros E, De Caterina R, Badimon L, Covas MI, et al. Olive 30 oil and health: summary of the II international conference on olive oil and health consensus report, Jaen 31 and Cordoba (Spain) 2008. Nutrition, metabolism, and cardiovascular diseases : NMCD. 32 2010;20(4):284-94. 33 7. Urpi-Sarda M, Casas R, Chiva-Blanch G, Romero-Mamani ES, Valderas-Martinez P, Arranz S, 34 et al. Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory 35 biomakers related to atherosclerosis. Pharmacological research : the official journal of the Italian 36 Pharmacological Society. 2012;65(6):577-83. 37 8. Martinez-Lapiscina EH, Clavero P, Toledo E, San Julian B, Sanchez-Tainta A, Corella D, et al. 38 Virgin olive oil supplementation and long-term cognition: the PREDIMED-NAVARRA randomized, 39 trial. The journal of nutrition, health & aging. 2013;17(6):544-52. 40

Silva et al 2015 New perspectives on bioactivity of olive oil
24
9. Kastorini CM, Milionis HJ, Goudevenos JA, Panagiotakos DB. Mediterranean diet and 41 coronary heart disease: is obesity a link? - A systematic review. Nutrition, metabolism, and 42 cardiovascular diseases : NMCD. 2010;20(7):536-51. 43 10. Razquin C, Martinez JA, Martinez-Gonzalez MA, Mitjavila MT, Estruch R, Marti A. A 3 years 44 follow-up of a Mediterranean diet rich in virgin olive oil is associated with high plasma antioxidant 45 capacity and reduced body weight gain. European journal of clinical nutrition. 2009;63(12):1387-93. 46 11. Schwingshackl L, Hoffmann G. Mediterranean dietary pattern, inflammation and endothelial 47 function: a systematic review and meta-analysis of intervention trials. Nutrition, metabolism, and 48 cardiovascular diseases : NMCD. 2014;24(9):929-39. 49 12. Schwingshackl L, Hoffmann G. Monounsaturated fatty acids, olive oil and health status: a 50 systematic review and meta-analysis of cohort studies. Lipids in health and disease. 2014;13:154. 51 13. Harwood J. AR. Handbook of olive oil analysis and properties 2000. 52 14. Servili M, Montedoro, G. . Contribution of phenolic compounds to virgin olive oil quality. 53 European Journal of Lipid Science and Technology. 2002;104:602-13. 54 15. Perez-Jimenez F, Ruano J, Perez-Martinez P, Lopez-Segura F, Lopez-Miranda J. The influence 55 of olive oil on human health: not a question of fat alone. Molecular nutrition & food research. 56 2007;51(10):1199-208. 57 16. Di Maio I, Esposto, S., Taticchi, A., Selvaggini, R., Veneziani, G., Urbani, S. , Servili, M. . 58 HPLC–ESI-MS investigation of tyrosol and hydroxytyrosol oxidation products in virgin olive oil. Food 59 Chemistry. 2011;125:21-8. 60 17. Brenes M, Garcia A, Garcia P, Garrido A. Acid hydrolysis of secoiridoid aglycons during 61 storage of virgin olive oil. Journal of agricultural and food chemistry. 2001;49(11):5609-14. 62 18. Hrncirik K. F, S. . Comparability and reliability of different techniques for the determination of 63 phenolic compounds in virgin olive oil. European Journal of Lipid Science and Technology. 64 2004;106:540-9. 65 19. Karkoula E, Skantzari A, Melliou E, Magiatis P. Direct measurement of oleocanthal and 66 oleacein levels in olive oil by quantitative (1)H NMR. Establishment of a new index for the 67 characterization of extra virgin olive oils. Journal of agricultural and food chemistry. 68 2012;60(47):11696-703. 69 20. Corona G, Tzounis X, Assunta Dessi M, Deiana M, Debnam ES, Visioli F, et al. The fate of 70 olive oil polyphenols in the gastrointestinal tract: implications of gastric and colonic microflora-71 dependent biotransformation. Free radical research. 2006;40(6):647-58. 72 21. Pinto J, Paiva-Martins F, Corona G, Debnam ES, Jose Oruna-Concha M, Vauzour D, et al. 73 Absorption and metabolism of olive oil secoiridoids in the small intestine. The British journal of 74 nutrition. 2011;105(11):1607-18. 75 22. Aranzazu Soler MPR, Alba Macià, Shikha Saha, Caroline S.M. Furniss, Paul A. Kroon, Maria 76 J. Motilva. Digestion stability and evaluation of the metabolism and transport of olive oil phenols in the 77 human small-intestinal epithelial Caco-2/TC7 cell line. Food Chemistry. 2010;119:703-14. 78 23. Vissers MN, Zock PL, Roodenburg AJ, Leenen R, Katan MB. Olive oil phenols are absorbed in 79 humans. The Journal of nutrition. 2002;132(3):409-17. 80 24. Khymenets O, Fito M, Tourino S, Munoz-Aguayo D, Pujadas M, Torres JL, et al. Antioxidant 81 activities of hydroxytyrosol main metabolites do not contribute to beneficial health effects after olive 82 oil ingestion. Drug metabolism and disposition: the biological fate of chemicals. 2010;38(9):1417-21. 83 25. Tuck KL, Hayball PJ, Stupans I. Structural characterization of the metabolites of 84 hydroxytyrosol, the principal phenolic component in olive oil, in rats. Journal of agricultural and food 85 chemistry. 2002;50(8):2404-9. 86

Silva et al 2015 New perspectives on bioactivity of olive oil
25
26. Kotronoulas A, Pizarro N, Serra A, Robledo P, Joglar J, Rubio L, et al. Dose-dependent 87 metabolic disposition of hydroxytyrosol and formation of mercapturates in rats. Pharmacological 88 research : the official journal of the Italian Pharmacological Society. 2013;77:47-56. 89 27. Laura Rubió AS, Alba Macià, Carme Piñol, Maria-Paz Romero, Maria-José Motilva. In vivo 90 distribution and deconjugation of hydroxytyrosol phase II metabolites in red blood cells: A potential 91 new target for hydroxytyrosol. Journal of functional foods. 2014;10:139-43. 92 28. Mosele JI, Martin-Pelaez S, Macia A, Farras M, Valls RM, Catalan U, et al. Faecal microbial 93 metabolism of olive oil phenolic compounds: in vitro and in vivo approaches. Molecular nutrition & 94 food research. 2014;58(9):1809-19. 95 29. Pashkow FJ. Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role 96 in Treatment and/or Prevention? International journal of inflammation. 2011;2011:514623. 97 30. Vlantis K, Pasparakis M. Role of TNF in pathologies induced by nuclear factor kappaB 98 deficiency. Current directions in autoimmunity. 2010;11:80-93. 99 31. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, et al. Phytochemistry: ibuprofen-like 100 activity in extra-virgin olive oil. Nature. 2005;437(7055):45-6. 101 32. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, et al. Ibuprofen-like activity in extra-102 virgin olive oil. Nature. 2005;437(7055):45-6. 103 33. Tulp M, Bruhn JG, Bohlin L. Food for thought. Drug discovery today. 2006;11(23-24):1115-21. 104 34. O’Connor Á. An overview of the role of diet in the treatment of rheumatoid arthritis. Nutrition 105 Bulletin. 2014;39(1):74-88. 106 35. Waterman E, Lockwood B. Active components and clinical applications of olive oil. Altern 107 Med Rev. 2007;12(4):331-42. 108 36. S. Silva BS, J. Rocha, R. Direito, A. Fernandes, D. Brites, M. Freitas, E. Fernandes, M. R. 109 Bronze, M. E. Figueira. Protective effects of hydroxytyrosol-supplemented refined olive oil in animal 110 models of acute inflammation and rheumatoid arthritis The Journal of nutritional biochemistry. 2015. 111 37. European Comission, Comission Regulation (EC) No 432/2012 of 16 May 2012. 112 38. Sanchez-Fidalgo S, Sanchez de Ibarguen L, Cardeno A, Alarcon de la Lastra C. Influence of 113 extra virgin olive oil diet enriched with hydroxytyrosol in a chronic DSS colitis model. European 114 journal of nutrition. 2012;51(4):497-506. 115 39. Rosillo MA, Alcaraz MJ, Sanchez-Hidalgo M, Fernandez-Bolanos JG, Alarcon-de-la-Lastra C, 116 Ferrandiz ML. Anti-inflammatory and joint protective effects of extra-virgin olive-oil polyphenol 117 extract in experimental arthritis. The Journal of nutritional biochemistry. 2014;25(12):1275-81. 118 40. Impellizzeri D, Esposito E, Mazzon E, Paterniti I, Di Paola R, Morittu VM, et al. Oleuropein 119 aglycone, an olive oil compound, ameliorates development of arthritis caused by injection of collagen 120 type II in mice. The Journal of pharmacology and experimental therapeutics. 2011;339(3):859-69. 121 41. Martinez-Dominguez E, de la Puerta R, Ruiz-Gutierrez V. Protective effects upon experimental 122 inflammation models of a polyphenol-supplemented virgin olive oil diet. Inflammation research : 123 official journal of the European Histamine Research Society [et al]. 2001;50(2):102-6. 124 42. Bignotto L, Rocha J, Sepodes B, Eduardo-Figueira M, Pinto R, Chaud M, et al. Anti-125 inflammatory effect of lycopene on carrageenan-induced paw oedema and hepatic ischaemia-126 reperfusion in the rat. The British journal of nutrition. 2009;102(1):126-33. 127 43. Gong D, Geng C, Jiang L, Cao J, Yoshimura H, Zhong L. Effects of hydroxytyrosol-20 on 128 carrageenan-induced acute inflammation and hyperalgesia in rats. Phytotherapy research : PTR. 129 2009;23(5):646-50. 130 44. Tuck KL, Freeman MP, Hayball PJ, Stretch GL, Stupans I. The in vivo fate of hydroxytyrosol 131 and tyrosol, antioxidant phenolic constituents of olive oil, after intravenous and oral dosing of labeled 132 compounds to rats. The Journal of nutrition. 2001;131(7):1993-6. 133

Silva et al 2015 New perspectives on bioactivity of olive oil
26
45. Gonzalez-Santiago M, Fonolla J, Lopez-Huertas E. Human absorption of a supplement 134 containing purified hydroxytyrosol, a natural antioxidant from olive oil, and evidence for its transient 135 association with low-density lipoproteins. Pharmacological research : the official journal of the Italian 136 Pharmacological Society. 2010;61(4):364-70. 137 46. Visioli F, Galli C, Grande S, Colonnelli K, Patelli C, Galli G, et al. Hydroxytyrosol excretion 138 differs between rats and humans and depends on the vehicle of administration. The Journal of nutrition. 139 2003;133(8):2612-5. 140 47. Miro-Casas E, Covas MI, Farre M, Fito M, Ortuno J, Weinbrenner T, et al. Hydroxytyrosol 141 disposition in humans. Clinical chemistry. 2003;49(6 Pt 1):945-52. 142 48. Hamden K, Allouche N, Damak M, Elfeki A. Hypoglycemic and antioxidant effects of phenolic 143 extracts and purified hydroxytyrosol from olive mill waste in vitro and in rats. Chemico-biological 144 interactions. 2009;180(3):421-32. 145 49. Sanchez de Medina V, Priego-Capote F, Luque de Castro MD. Characterization of refined 146 edible oils enriched with phenolic extracts from olive leaves and pomace. Journal of agricultural and 147 food chemistry. 2012;60(23):5866-73. 148 50. Suarez M, Romero MP, Motilva MJ. Development of a phenol-enriched olive oil with phenolic 149 compounds from olive cake. Journal of agricultural and food chemistry. 2010;58(19):10396-403. 150 51. Gimeno E, de la Torre-Carbot K, Lamuela-Raventos RM, Castellote AI, Fito M, de la Torre R, 151 et al. Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A 152 randomized crossover controlled trial. The British journal of nutrition. 2007;98(6):1243-50. 153 52. Covas MI, Nyyssonen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, et al. The effect 154 of polyphenols in olive oil on heart disease risk factors: a randomized trial. Annals of internal 155 medicine. 2006;145(5):333-41. 156 53. Covas MI, de la Torre K, Farre-Albaladejo M, Kaikkonen J, Fito M, Lopez-Sabater C, et al. 157 Postprandial LDL phenolic content and LDL oxidation are modulated by olive oil phenolic compounds 158 in humans. Free radical biology & medicine. 2006;40(4):608-16. 159 54. Fito M, Cladellas M, de la Torre R, Marti J, Alcantara M, Pujadas-Bastardes M, et al. 160 Antioxidant effect of virgin olive oil in patients with stable coronary heart disease: a randomized, 161 crossover, controlled, clinical trial. Atherosclerosis. 2005;181(1):149-58. 162 55. Weinbrenner T, Fito M, de la Torre R, Saez GT, Rijken P, Tormos C, et al. Olive oils high in 163 phenolic compounds modulate oxidative/antioxidative status in men. The Journal of nutrition. 164 2004;134(9):2314-21. 165 56. Marrugat J, Covas MI, Fito M, Schroder H, Miro-Casas E, Gimeno E, et al. Effects of differing 166 phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial. 167 European journal of nutrition. 2004;43(3):140-7. 168 57. Ruiz-Canela M, Martinez-Gonzalez MA. Olive oil in the primary prevention of cardiovascular 169 disease. Maturitas. 2011;68(3):245-50. 170 58. Katan MB, Zock PL, Mensink RP. Effects of fats and fatty acids on blood lipids in humans: an 171 overview. The American journal of clinical nutrition. 1994;60(6 Suppl):1017S-22S. 172 59. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the 173 Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA 174 Study. Journal of the American College of Cardiology. 2004;44(1):152-8. 175 60. Huang CL, Sumpio BE. Olive oil, the mediterranean diet, and cardiovascular health. Journal of 176 the American College of Surgeons. 2008;207(3):407-16. 177 61. Covas MI, Konstantinidou V, Fito M. Olive oil and cardiovascular health. Journal of 178 cardiovascular pharmacology. 2009;54(6):477-82. 179 62. Krauss RM, Dreon DM. Low-density-lipoprotein subclasses and response to a low-fat diet in 180 healthy men. The American journal of clinical nutrition. 1995;62(2):478S-87S. 181

Silva et al 2015 New perspectives on bioactivity of olive oil
27
63. Bos G, Poortvliet MC, Scheffer PG, Dekker JM, Ocke MC, Nijpels G, et al. Dietary 182 polyunsaturated fat intake is associated with low-density lipoprotein size, but not with susceptibility to 183 oxidation in subjects with impaired glucose metabolism and type II diabetes: the Hoorn study. 184 European journal of clinical nutrition. 2007;61(2):205-11. 185 64. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density 186 lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. 187 The American journal of medicine. 1993;94(4):350-6. 188 65. Aguilera CM, Mesa MD, Ramirez-Tortosa MC, Nestares MT, Ros E, Gil A. Sunflower oil does 189 not protect against LDL oxidation as virgin olive oil does in patients with peripheral vascular disease. 190 Clinical nutrition. 2004;23(4):673-81. 191 66. Kratz M, Cullen P, Kannenberg F, Kassner A, Fobker M, Abuja PM, et al. Effects of dietary 192 fatty acids on the composition and oxidizability of low-density lipoprotein. European journal of clinical 193 nutrition. 2002;56(1):72-81. 194 67. FDA. FDA Allows Qualified Health Claim to Decrease Risk of Coronary Heart Disease 2004. 195 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108368.htm]. 196 68. Fuentes F, Lopez-Miranda J, Perez-Martinez P, Jimenez Y, Marin C, Gomez P, et al. Chronic 197 effects of a high-fat diet enriched with virgin olive oil and a low-fat diet enriched with alpha-linolenic 198 acid on postprandial endothelial function in healthy men. The British journal of nutrition. 199 2008;100(1):159-65. 200 69. Capurso C, Massaro M, Scoditti E, Vendemiale G, Capurso A. Vascular effects of the 201 Mediterranean diet Part I: Anti-hypertensive and anti-thrombotic effects. Vascular pharmacology. 202 2014;63(3):118-26. 203 70. Khurana S, Venkataraman K, Hollingsworth A, Piche M, Tai TC. Polyphenols: benefits to the 204 cardiovascular system in health and in aging. Nutrients. 2013;5(10):3779-827. 205 71. Scientific Opinion on the substantiation of health claims related to polyphenols in olive and 206 protection of LDL particles from oxidative damage (ID 1333, 1638, 1639, 1696, 2865), maintenance of 207 normal blood HDL-cholesterol concentrations (ID 1639), maintenance of normal blood pressure (ID 208 3781), “anti-inflammatory properties” (ID 1882), “contributes to the upper respiratory tract health” (ID 209 3468), “can help to maintain a normal function of gastrointestinal tract” (3779), and “contributes to 210 body defences against external agents” (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 211 1924/20061. EFSA Journal. 2011;9 (4)(2033). 212 72. Scientific Opinion on the substantiation of health claims related to olive oil and maintenance of 213 normal blood LDL-cholesterol concentrations (ID 1316, 1332), maintenance of normal (fasting) blood 214 concentrations of triglycerides (ID 1316, 1332), maintenance of normal blood HDL-cholesterol 215 concentrations (ID 1316, 1332) and maintenance of normal blood glucose concentrations (ID 4244) 216 pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal. 2011 9 (4)(2044). 217 73. Vissers MN, Zock PL, Katan MB. Bioavailability and antioxidant effects of olive oil phenols in 218 humans: a review. European journal of clinical nutrition. 2004;58(6):955-65. 219 74. Rietjens SJ, Bast A, Haenen GR. New insights into controversies on the antioxidant potential of 220 the olive oil antioxidant hydroxytyrosol. Journal of agricultural and food chemistry. 2007;55(18):7609-221 14. 222 75. Mastralexi A, Nenadis N, Tsimidou MZ. Addressing analytical requirements to support health 223 claims on "olive oil polyphenols" (EC Regulation 432/2012). Journal of agricultural and food 224 chemistry. 2014;62(12):2459-61. 225 76. Romero C, Brenes M. Analysis of total contents of hydroxytyrosol and tyrosol in olive oils. 226 Journal of agricultural and food chemistry. 2012;60(36):9017-22. 227

Silva et al 2015 New perspectives on bioactivity of olive oil
28
77. Teres S, Barcelo-Coblijn G, Benet M, Alvarez R, Bressani R, Halver JE, et al. Oleic acid 228 content is responsible for the reduction in blood pressure induced by olive oil. Proceedings of the 229 National Academy of Sciences of the United States of America. 2008;105(37):13811-6. 230 78. Yang Q, Alemany R, Casas J, Kitajka K, Lanier SM, Escriba PV. Influence of the membrane 231 lipid structure on signal processing via G protein-coupled receptors. Molecular pharmacology. 232 2005;68(1):210-7. 233 79. Lahey R, Wang X, Carley AN, Lewandowski ED. Dietary fat supply to failing hearts 234 determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. 235 Circulation. 2014;130(20):1790-9. 236 80. Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Woodcock SR, Cole MP, et al. Endogenous 237 generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and 238 reperfusion. Cardiovascular research. 2010;85(1):155-66. 239 81. Coles B, Bloodsworth A, Clark SR, Lewis MJ, Cross AR, Freeman BA, et al. Nitrolinoleate 240 inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel 241 antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circulation 242 research. 2002;91(5):375-81. 243 82. Coles B, Bloodsworth A, Eiserich JP, Coffey MJ, McLoughlin RM, Giddings JC, et al. 244 Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing 245 phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. The Journal of 246 biological chemistry. 2002;277(8):5832-40. 247 83. Charles RL, Rudyk O, Prysyazhna O, Kamynina A, Yang J, Morisseau C, et al. Protection from 248 hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble 249 epoxide hydrolase. Proceedings of the National Academy of Sciences of the United States of America. 250 2014;111(22):8167-72. 251 84. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. 252 Journal of hypertension. 2000;18(6):655-73. 253 85. Sugamura K, Keaney JF, Jr. Reactive oxygen species in cardiovascular disease. Free radical 254 biology & medicine. 2011;51(5):978-92. 255 86. Raedschelders K, Ansley DM, Chen DD. The cellular and molecular origin of reactive oxygen 256 species generation during myocardial ischemia and reperfusion. Pharmacology & therapeutics. 257 2012;133(2):230-55. 258 87. Ross R. Atherosclerosis--an inflammatory disease. The New England journal of medicine. 259 1999;340(2):115-26. 260 88. Dell'Agli M, Fagnani R, Galli GV, Maschi O, Gilardi F, Bellosta S, et al. Olive oil phenols 261 modulate the expression of metalloproteinase 9 in THP-1 cells by acting on nuclear factor-kappaB 262 signaling. Journal of agricultural and food chemistry. 2010;58(4):2246-52. 263 89. Dell'Agli M, Fagnani R, Mitro N, Scurati S, Masciadri M, Mussoni L, et al. Minor components 264 of olive oil modulate proatherogenic adhesion molecules involved in endothelial activation. Journal of 265 agricultural and food chemistry. 2006;54(9):3259-64. 266 90. Gonzalez-Correa JA, Navas MD, Munoz-Marin J, Trujillo M, Fernandez-Bolanos J, de la Cruz 267 JP. Effects of hydroxytyrosol and hydroxytyrosol acetate administration to rats on platelet function 268 compared to acetylsalicylic acid. Journal of agricultural and food chemistry. 2008;56(17):7872-6. 269 91. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovascular research. 270 2006;69(3):625-35. 271 92. Barderas MG, Vivanco F, Alvarez-Llamas G. Vascular proteomics. Methods in molecular 272 biology. 2013;1000:1-20. 273

Silva et al 2015 New perspectives on bioactivity of olive oil
29
93. von Zur Muhlen C, Schiffer E, Zuerbig P, Kellmann M, Brasse M, Meert N, et al. Evaluation of 274 urine proteome pattern analysis for its potential to reflect coronary artery atherosclerosis in 275 symptomatic patients. Journal of proteome research. 2009;8(1):335-45. 276 94. Zimmerli LU, Schiffer E, Zurbig P, Good DM, Kellmann M, Mouls L, et al. Urinary proteomic 277 biomarkers in coronary artery disease. Molecular & cellular proteomics : MCP. 2008;7(2):290-8. 278 95. Kalela A, Koivu TA, Sisto T, Kanervisto J, Hoyhtya M, Sillanaukee P, et al. Serum matrix 279 metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scandinavian 280 journal of clinical and laboratory investigation. 2002;62(5):337-42. 281 96. Scoditti E, Nestola A, Massaro M, Calabriso N, Storelli C, De Caterina R, et al. Hydroxytyrosol 282 suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKCalpha 283 and PKCbeta1 inhibition. Atherosclerosis. 2014;232(1):17-24. 284 97. Scoditti E, Calabriso N, Massaro M, Pellegrino M, Storelli C, Martines G, et al. Mediterranean 285 diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human 286 vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and 287 cancer. Archives of biochemistry and biophysics. 2012;527(2):81-9. 288 98. Delles C, Schiffer E, von Zur Muhlen C, Peter K, Rossing P, Parving HH, et al. Urinary 289 proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. 290 Journal of hypertension. 2010;28(11):2316-22. 291 99. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 292 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. Journal of cellular 293 physiology. 2002;192(2):160-70. 294 100. Lafleur MA, Hollenberg MD, Atkinson SJ, Knauper V, Murphy G, Edwards DR. Activation of 295 pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in 296 human umbilical vein endothelial cells and generates a distinct 63 kDa active species. The Biochemical 297 journal. 2001;357(Pt 1):107-15. 298 101. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species 299 produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases 300 in vitro. Implications for atherosclerotic plaque stability. The Journal of clinical investigation. 301 1996;98(11):2572-9. 302 102. Oak MH, El Bedoui J, Anglard P, Schini-Kerth VB. Red wine polyphenolic compounds 303 strongly inhibit pro-matrix metalloproteinase-2 expression and its activation in response to thrombin 304 via direct inhibition of membrane type 1-matrix metalloproteinase in vascular smooth muscle cells. 305 Circulation. 2004;110(13):1861-7. 306 103. El Bedoui J, Oak MH, Anglard P, Schini-Kerth VB. Catechins prevent vascular smooth muscle 307 cell invasion by inhibiting MT1-MMP activity and MMP-2 expression. Cardiovascular research. 308 2005;67(2):317-25. 309 104. Silva S, Bronze MR, Figueira ME, Siwy J, Mischak H, Combet E, et al. Impact of a 6-wk olive 310 oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, 311 chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind 312 study. The American journal of clinical nutrition. 2015;101(1):44-54. 313 105. Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, van der Heijden R, et al. 314 Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular 315 pharmacology. Phytotherapy research : PTR. 2005;19(3):173-82. 316 106. Finley Austin MJ, Babiss L. Commentary: where and how could biomarkers be used in 2016? 317 The AAPS journal. 2006;8(1):E185-9. 318 107. Schanstra JP, Mischak H. Proteomic urinary biomarker approach in renal disease: from 319 discovery to implementation. Pediatric nephrology. 2014. 320

Silva et al 2015 New perspectives on bioactivity of olive oil
30
108. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, et al. 321 Recommendations for biomarker identification and qualification in clinical proteomics. Science 322 translational medicine. 2010;2(46):46ps2. 323 109. Stegemann C, Didangelos A, Barallobre-Barreiro J, Langley SR, Mandal K, Jahangiri M, et al. 324 Proteomic identification of matrix metalloproteinase substrates in the human vasculature. Circ-325 Cardiovasc Gene. 2013;6(Article):106-17. 326 110. Mischak H, Rossing P. Proteomic biomarkers in diabetic nephropathy--reality or future 327 promise? Nephrology, dialysis, transplantation : official publication of the European Dialysis and 328 Transplant Association - European Renal Association. 2010;25(9):2843-5. 329 111. Lescuyer P, Hochstrasser D, Rabilloud T. How shall we use the proteomics toolbox for 330 biomarker discovery? J Proteome Res. 2007;6(9):3371-6. 331 112. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for 332 proteome analysis. Nat Methods. 2009;6(5):359-62. 333 113. Husi H, Van Agtmael T, Mullen W, Bahlmann FH, Schanstra JP, Vlahou A, et al. Proteome-334 Based Systems Biology Analysis of the Diabetic Mouse Aorta Reveals Major Changes in Fatty Acid 335 Biosynthesis as Potential Hallmark in Diabetes Mellitus-Associated Vascular Disease. Circ-Cardiovasc 336 Gene. 2014;7(2):161-70. 337 114. Thongboonkerd V, McLeish KR, Arthur JM, Klein JB. Proteomic analysis of normal human 338 urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney international. 339 2002;62(4):1461-9. 340 115. Thongboonkerd V, Malasit P. Renal and urinary proteomics: current applications and 341 challenges. Proteomics. 2005;5(4):1033-42. 342 116. Mischak H, Kolch W, Aivaliotis M, Bouyssie D, Court M, Dihazi H, et al. Comprehensive 343 human urine standards for comparability and standardization in clinical proteome analysis. Proteomics 344 Clinical applications. 2010;4(4):464-78. 345 117. Albalat A, Franke J, Gonzalez J, Mischak H, Zurbig P. Urinary proteomics based on capillary 346 electrophoresis coupled to mass spectrometry in kidney disease. Methods in molecular biology. 347 2013;919:203-13. 348 118. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, Coon JJ, et al. Naturally occurring 349 human urinary peptides for use in diagnosis of chronic kidney disease. Molecular & cellular proteomics 350 : MCP. 2010;9(11):2424-37. 351 119. Metzger J, Kirsch T, Schiffer E, Ulger P, Mentes E, Brand K, et al. Urinary excretion of twenty 352 peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney international. 353 2010;78(12):1252-62. 354 120. Dawson J, Walters M, Delles C, Mischak H, Mullen W. Urinary proteomics to support 355 diagnosis of stroke. PloS one. 2012;7(5):e35879. 356 121. Mischak H, Schanstra JP. CE-MS in biomarker discovery, validation, and clinical application. 357 Proteomics Clinical applications. 2011;5(1-2):9-23. 358 122. Coon JJ, Zurbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, et al. CE-MS analysis of 359 the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clinical 360 applications. 2008;2(7-8):964. 361 123. Lee RT, Libby P. The unstable atheroma. Arteriosclerosis, thrombosis, and vascular biology. 362 1997;17(10):1859-67. 363 124. Zurbig P, Jerums G, Hovind P, Macisaac RJ, Mischak H, Nielsen SE, et al. Urinary proteomics 364 for early diagnosis in diabetic nephropathy. Diabetes. 2012;61(12):3304-13. 365 125. de Roos B, Zhang X, Rodriguez Gutierrez G, Wood S, Rucklidge GJ, Reid MD, et al. Anti-366 platelet effects of olive oil extract: in vitro functional and proteomic studies. European journal of 367 nutrition. 2011;50(7):553-62. 368

Silva et al 2015 New perspectives on bioactivity of olive oil
31
126. Arbones-Mainar JM, Ross K, Rucklidge GJ, Reid M, Duncan G, Arthur JR, et al. Extra virgin 369 olive oils increase hepatic fat accumulation and hepatic antioxidant protein levels in APOE-/- mice. 370 Journal of proteome research. 2007;6(10):4041-54. 371 127. Ge Y, Wang TJ. Identifying novel biomarkers for cardiovascular disease risk prediction. Journal 372 of internal medicine. 2012;272(5):430-9. 373 128. Sharma P, Cosme J, Gramolini AO. Recent advances in cardiovascular proteomics. J 374 Proteomics. 2013;81:3-14. 375 129. Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, et al. Advances 376 in urinary proteome analysis and biomarker discovery. Journal of the American Society of Nephrology. 377 2007;18(4):1057-71. 378 130. Julian BA, Suzuki H, Suzuki Y, Tomino Y, Spasovski G, Novak J. Sources of urinary proteins 379 and their analysis by urinary proteomics for the detection of biomarkers of disease. Proteom Clin Appl. 380 2009;3(9):1029-43. 381 131. Perona JS, Cabello-Moruno R, Ruiz-Gutierrez V. The role of virgin olive oil components in the 382 modulation of endothelial function. The Journal of nutritional biochemistry. 2006;17(7):429-45. 383 132. Guillen N, Acin S, Navarro MA, Perona JS, Arbones-Mainar JM, Arnal C, et al. Squalene in a 384 sex-dependent manner modulates atherosclerotic lesion which correlates with hepatic fat content in 385 apoE-knockout male mice. Atherosclerosis. 2008;197(1):72-83. 386 133. Monte E, Vondriska TM. Epigenomes: the missing heritability in human cardiovascular 387 disease? Proteomics Clinical applications. 2014;8(7-8):480-7. 388 134. Konstantinidou V, Covas MI, Munoz-Aguayo D, Khymenets O, de la Torre R, Saez G, et al. In 389 vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a 390 randomized controlled trial. FASEB journal : official publication of the Federation of American 391 Societies for Experimental Biology. 2010;24(7):2546-57. 392 135. Camargo A, Ruano J, Fernandez JM, Parnell LD, Jimenez A, Santos-Gonzalez M, et al. Gene 393 expression changes in mononuclear cells in patients with metabolic syndrome after acute intake of 394 phenol-rich virgin olive oil. BMC genomics. 2010;11:253. 395 136. Vazquez-Fresno R, Llorach R, Urpi-Sarda M, Lupianez-Barbero A, Estruch R, Corella D, et al. 396 Metabolomic Pattern Analysis after Mediterranean Diet Intervention in a Nondiabetic Population: A 1- 397 and 3-Year Follow-up in the PREDIMED Study. Journal of proteome research. 2015;14(1):531-40. 398 137. Noratto GD, Angel-Morales G, Talcott ST, Mertens-Talcott SU. Polyphenolics from acai ( 399 Euterpe oleracea Mart.) and red muscadine grape (Vitis rotundifolia ) protect human umbilical vascular 400 Endothelial cells (HUVEC) from glucose- and lipopolysaccharide (LPS)-induced inflammation and 401 target microRNA-126. Journal of agricultural and food chemistry. 2011;59(14):7999-8012. 402 138. Milenkovic D, Jude B, Morand C. miRNA as molecular target of polyphenols underlying their 403 biological effects. Free radical biology & medicine. 2013;64:40-51. 404 139. Garcia-Gonzalez DL, Aparicio R. Research in olive oil: challenges for the near future. Journal 405 of agricultural and food chemistry. 2010;58(24):12569-77. 406 140. Martin-Pelaez S, Covas MI, Fito M, Kusar A, Pravst I. Health effects of olive oil polyphenols: 407 recent advances and possibilities for the use of health claims. Molecular nutrition & food research. 408 2013;57(5):760-71. 409 141. Dunn MJ. Proteomics clinical applications reviews 2013. Proteomics Clinical applications. 410 2013;7(1-2):4-7. 411 142. Levi B, Werman MJ. Long-term fructose consumption accelerates glycation and several age-412 related variables in male rats. J Nutr. 1998;128(9):1442-9. 413 143. Kontogianni VG, Charisiadis P, Margianni E, Lamari FN, Gerothanassis IP, Tzakos AG. Olive 414 leaf extracts are a natural source of advanced glycation end product inhibitors. Journal of medicinal 415 food. 2013;16(9):817-22. 416

Silva et al 2015 New perspectives on bioactivity of olive oil
32
144. Vlassopoulos A, Lean ME, Combet E. Protein-phenolic interactions and inhibition of glycation 417 - combining a systematic review and experimental models for enhanced physiological relevance. Food 418 & function. 2014;5(10):2646-55. 419 420

Silva et al 2015 New perspectives on bioactivity of olive oil
33
Figure 1 – Chronic inflammation model and impact on rats paw edema (ANOVA, * p < 0.001
vs. postive control – Rheumatoid Arthritis, + p < 0.01 vs. Refined Olive Oil; OHTYR =
hydroxytyrosol) (adapted from Silva et al.(36))